COCA: Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT04910633
Collaborator
(none)
44
1
1.7
26.3

Study Details

Study Description

Brief Summary

An article to present how cancer patients were taken in charge at Lyon University Hospital Cancer Institute (France) during the first peak of the COVID-19 pandemic between March and May 2020 is under writing.

It will present strategies that were set-up to avoid cross-contamination between patients and caregivers, patients treatment adaptation (timing, dosage,..) and how consultations, multidisciplinary team meetings, surgical procedures and clinical trials were impacted.

Part of this article will also illustrate the characteristics of patients with a solid tumor(s) that have been hospitalized during this timeframe for the COVID-19. How cancer type and stage affect Covid severity and mortality.will be described for a small sample of patients (44). These qualitative figures will be compared to literature current state of the art.

Condition or Disease Intervention/Treatment Phase
  • Other: COCA is an observational study based on retrospective data issued from patient medial file.

Study Design

Study Type:
Observational
Actual Enrollment :
44 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach
Actual Study Start Date :
Dec 2, 2020
Actual Primary Completion Date :
Dec 9, 2020
Actual Study Completion Date :
Jan 22, 2021

Arms and Interventions

Arm Intervention/Treatment
Solid Tumor and COVID-19

Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.

Other: COCA is an observational study based on retrospective data issued from patient medial file.
The following parameters will be collected from the medical files of the patients involved in this study: Age Gender Cancer type Cancer Stage Cancer Treatment COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%) Living Status Attribution of Mortality to COVID status Comorbidities

Outcome Measures

Primary Outcome Measures

  1. Illustration of the repartition of COVID+ patient severity (Low/Medium/Severe status) depending on cancer nature, stage and patient age. [At the end of Month 1]

    COVID-19 severity will be determined based on chest X-Ray damage as follow. Low severity : ≤25% of chest X-Ray damage, Middle severity: between 25-50% of chest X-Ray damage, High Severity : above 50% of chest X-Ray damage. A graphic will then be drafted to present the relationship between Covid-19 severity depending on patient age, cancer nature, and cancer stage.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with a LUHCI code created after 2015 and a LUHCI COVID-19 code created between March 2020 and May 2020.
Exclusion Criteria:
  • Patients who did not allow the reuse of their medical file data for research related to COVID-19-

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lyon University Hospital Cancer Institute Bron France 69 677

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT04910633
Other Study ID Numbers:
  • 69HCL21_0005
First Posted:
Jun 2, 2021
Last Update Posted:
Jun 2, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2021